EWTX
Edgewise Therapeutics Inc
41.10$
-7.8%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | |
| – | +50.4% | +47.0% | +97.8% | +221.9% | +32.2% | -1.0% | |
| – | – | – | – | – | – | – | |
| – | +71.6% | +117.5% | -48.4% | +447.2% | +39.7% | +19.2% | |
| – | +69.9% | +399.1% | -50.4% | +329.0% | +35.9% | +25.6% | |
| – | +71.4% | +154.1% | -48.9% | +417.9% | +38.9% | +19.1% | |
| – | – | – | – | – | – | – | |
| – | – | +294.2% | +1,377.2% | – | – | – | |
| – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.